Extracorporeal Photopheresis | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its extracorporeal photopheresis coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.

CMS extracorporeal photopheresis coverage policy changes don't happen often — which is exactly why this one deserves your attention now, not after your next denial. The Centers for Medicare & Medicaid Services updated its policy governing extracorporeal photopheresis (ECP), a specialized apheresis-based treatment used for conditions like graft-versus-host disease and cutaneous T-cell lymphoma. The policy does not list specific CPT or HCPCS codes in the available data — but the coverage criteria and medical necessity framework are what drive reimbursement decisions here, and those are what you need to get right.

Quick-Reference Table

CMS Extracorporeal Photopheresis Coverage Criteria and Medical Necessity Requirements 2026

Extracorporeal photopheresis is not a high-volume procedure. But when it's indicated, it's expensive — and CMS scrutinizes ECP claims closely for medical necessity and proper documentation. A claim denial on an ECP case can mean tens of thousands of dollars in write-offs.

ECP involves withdrawing a patient's blood, treating the white blood cells with a photoactive drug (typically methoxsalen), exposing them to ultraviolet A light, and then returning the treated cells to the patient. CMS covers this procedure for specific approved indications. Coverage outside those indications is where claims fall apart.

Because the available policy data does not include the full modified text, the specific changes CMS made effective May 15, 2026 are not reproduced here verbatim. However, the modification to this coverage policy signals that your billing team should verify that current documentation practices still align with whatever criteria CMS has revised. Pull the updated policy directly at app.payerpolicy.org/p/cms/113-v3. before May 15, 2026.

What hasn't changed historically: CMS has required that extracorporeal photopheresis billing be supported by documentation showing a confirmed diagnosis, failed or contraindicated first-line therapy, and treating physician attestation of medical necessity. If the 2026 modification tightened any of those requirements, undocumented claims submitted after the effective date will face denial.

Prior authorization requirements for ECP vary by Medicare Advantage plan and MAC jurisdiction. If your patients are enrolled in Medicare Advantage, check each plan's prior auth requirements separately — the CMS national policy sets the floor, but MA plans layer additional requirements on top. Don't assume a CMS policy update automatically flows through to your MA contracts.

CMS Extracorporeal Photopheresis Exclusions and Non-Covered Indications

CMS has historically drawn a clear line between covered and non-covered uses of ECP. The covered indications have been narrow. Everything else sits in experimental or investigational territory — and CMS does not reimburse experimental procedures under Medicare fee-for-service.

Historically non-covered uses of ECP have included treatment for solid organ transplant rejection (outside specific circumstances), certain autoimmune conditions without sufficient clinical evidence, and uses not supported by the established evidence base CMS relies on for coverage determinations. This is where most claim denials originate — not from billing errors, but from submitting ECP claims for diagnoses CMS hasn't approved.

If your facility has been billing ECP for indications beyond graft-versus-host disease or cutaneous T-cell lymphoma, review the updated 2026 policy language carefully. A modification that narrows covered indications — or adds new documentation requirements — requires your clinical team to be looped in, not just your billing team. Talk to your compliance officer before May 15, 2026 if you're unsure how the changes affect your patient population.

Coverage Indications at a Glance

The available policy data does not include a detailed, indication-level breakdown from the modified policy text. The table below reflects historically established CMS coverage positions on ECP. Verify each row against the updated May 15, 2026 policy before billing.

Verify all rows against the updated May 15, 2026 CMS policy. Coverage positions may have changed in this modification.

CMS Extracorporeal Photopheresis Billing Guidelines and Action Items 2026

The effective date of May 15, 2026 gives you a clear deadline. Here's what your team needs to do before that date.

CPT, HCPCS, and ICD-10 Codes for Extracorporeal Photopheresis Under This Policy

The available policy data does not list specific CPT, HCPCS, or ICD-10 codes for this policy modification. Do NOT use this section as the basis for coding decisions.

A Note on ECP Coding

Your coding team should verify the correct procedure code(s) for extracorporeal photopheresis against the updated CMS policy language and your MAC's guidance. ECP is a specialized apheresis procedure, and correct code selection depends on the specific method, setting, and payer requirements. Miscoded ECP claims — particularly if billed under the wrong HCPCS or CPT code — create both claim denial risk and compliance exposure.

When the updated policy text specifies applicable codes, update your charge capture and encoder accordingly. If your coding team is uncertain, escalate to a certified coding specialist with experience in apheresis and hematology billing before the May 15, 2026 effective date.